OGI vs. CRMD, ABUS, PHAR, IMTX, ORIC, RAPP, SEPN, PGEN, STOK, and CGEM
Should you be buying Organigram stock or one of its competitors? The main competitors of Organigram include CorMedix (CRMD), Arbutus Biopharma (ABUS), Pharming Group (PHAR), Immatics (IMTX), ORIC Pharmaceuticals (ORIC), Rapport Therapeutics (RAPP), Septerna (SEPN), Precigen (PGEN), Stoke Therapeutics (STOK), and Cullinan Therapeutics (CGEM). These companies are all part of the "pharmaceutical products" industry.
Organigram vs.
Organigram (NASDAQ:OGI) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, risk, valuation, profitability and dividends.
Organigram received 173 more outperform votes than CorMedix when rated by MarketBeat users. However, 75.76% of users gave CorMedix an outperform vote while only 70.71% of users gave Organigram an outperform vote.
Organigram has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, CorMedix has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500.
34.6% of Organigram shares are held by institutional investors. Comparatively, 34.2% of CorMedix shares are held by institutional investors. 0.1% of Organigram shares are held by insiders. Comparatively, 5.2% of CorMedix shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
CorMedix has a net margin of 0.00% compared to Organigram's net margin of -31.69%. Organigram's return on equity of -8.59% beat CorMedix's return on equity.
Organigram has higher revenue and earnings than CorMedix. CorMedix is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks.
CorMedix has a consensus price target of $15.67, indicating a potential upside of 54.66%. Given CorMedix's higher probable upside, analysts clearly believe CorMedix is more favorable than Organigram.
In the previous week, Organigram had 7 more articles in the media than CorMedix. MarketBeat recorded 9 mentions for Organigram and 2 mentions for CorMedix. Organigram's average media sentiment score of 0.52 beat CorMedix's score of 0.00 indicating that Organigram is being referred to more favorably in the media.
Summary
Organigram beats CorMedix on 10 of the 17 factors compared between the two stocks.
Get Organigram News Delivered to You Automatically
Sign up to receive the latest news and ratings for OGI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Organigram Competitors List
Related Companies and Tools
This page (NASDAQ:OGI) was last updated on 2/22/2025 by MarketBeat.com Staff
Free OGI Stock Alerts